Comparative Pharmacology
Head-to-head clinical analysis: DORAL versus FLURAZEPAM HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORAL versus FLURAZEPAM HYDROCHLORIDE.
DORAL vs FLURAZEPAM HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
Positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA by increasing the frequency of chloride channel opening.
15-30 mg orally at bedtime, maximum 60 mg/day.
15-30 mg orally at bedtime as a single dose for insomnia; maximum dose 30 mg/day.
None Documented
None Documented
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Terminal elimination half-life: 40-114 hours (mean 74 hours); accumulates extensively with repeated dosing, leading to prolonged sedation.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Renal: 90% (as metabolites, <1% unchanged); Fecal: <10%; Biliary excretion minimal.
Category C
Category D/X
Benzodiazepine
Benzodiazepine